IceCure Taps Nasdaq CFO Veteran as Commercial Momentum Builds
Event summary
- IceCure Medical appoints Meir Peleg as CFO, effective May 17, 2026, bringing 20+ years of Nasdaq-listed company financial leadership.
- Company plans to appoint Dr. Richard Fine as Medical Director in Q2 2026 to lead breast indications.
- IceCure initiates search for new Chief Technology Officer following Naum Muchnik's departure on April 12, 2026.
- ProSense® cryoablation system gains commercial traction post-FDA clearance for low-risk breast cancer.
The big picture
IceCure's CFO appointment comes as the company capitalizes on FDA clearance and ASBrS recommendations for its ProSense® system in low-risk breast cancer. The move signals strategic focus on scaling commercial operations while navigating leadership transitions in technology and medical directives. The cryoablation market is increasingly competitive, with minimally invasive alternatives gaining traction in oncology.
What we're watching
- Commercial Execution
- How Peleg's capital markets expertise will support IceCure's scaling efforts amid growing ProSense® adoption.
- Regulatory Momentum
- Whether the FDA-approved ChoICE study will further validate ProSense® in low-risk breast cancer treatment.
- Leadership Stability
- The pace at which IceCure fills the CTO role and integrates new leadership into its technological roadmap.
Related topics